VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update
* Strong balance sheet with approximately $27.9 million in cash and cash equivalents * Strengthened the Company's veterinary leadership team to drive commercial focus * Expanded the Company's intellectual property portfolio * Published two clinical papers * Continued focus on, and made s...
VolitionRx Limited Schedules Second Quarter 2021 Earnings Conference Call and Business Update
AUSTIN, Texas, Aug. 4, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onThursday, August 12, at 8:00 a.m. Eastern time to discuss its financial and operating results for the second quarter of 2021, in addition to providing...
Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring
AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working w...
VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update
* Secured strongest-ever balance sheet with approximately $33.1 million in cash * Strengthened the Company's leadership team to drive commercial focus * Expanded the Company's intellectual property portfolio * Initiated production of product components at scale at the Company's Silver One ...
VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update
AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onWednesday May 12, at 8:00 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2021, in addition to providing a bu...
VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper
AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...
VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary
AUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...
VolitionRx Limited Appoints Two New Directors
AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...
New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis
AUSTIN, Texas, March 17, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working ...
VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update
AUSTIN, Texas, March 16, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 23, at 8:00 a.m. Eastern time to discuss its financial and operating results for the full fiscal year 2020, in addition to providing ...
VolitionRx Limited to Present at Conferences in March 2021
AUSTIN, Texas, March 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer,Cameron Reynolds, and its Executive Vice President, Investor Relations, Scott Powell, are scheduled to present at six conferences inMarch 2021. Duri...
VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock
AUSTIN, Texas, Feb. 12, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers ...
VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock
AUSTIN, Texas, Feb. 10, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers ...
VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts
AUSTIN, Texas, Feb. 2, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today provided a business update and announced the appointment of a new Chief Financial Officer, Mr. Terig Hughes, in addition to the appointment of Dr.Gaetan Michel as Chief Operating Officer, Mr. G...
VolitionRx Limited Opens its New Manufacturing Facility in Belgium
AUSTIN, Texas, Jan. 25, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the opening of "Silver One", its 10,000 square foot dedicated manufacturing facility located on the same science park as its Research and Development laboratory in Isnes,Belgium. Vol...
VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive Funding
AUSTIN, Texas, Jan. 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it has been awarded additional non-dilutive funding totaling approximately$4 million from the Walloon Region and Namur Invest,Belgium. To date, Agencies from the Walloon Region have a...
VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors
AUSTIN, Texas, Dec. 3, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the...
Volition Launches Nu.Q™ Vet Cancer Screening Test in the U.S.
AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has announced the l...
VolitionRx Limited to Present COVID-19 Data at MEDICA 2020
AUSTIN, Nov. 19, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases, has announced that Dr.Mark Eccleston, a founding sci...
Volition Veterinary Presents Expert Report Ahead of First Product Launch
* A Look to the Future of Cancer Diagnostics compiles insight from four veterinary cancer experts * Report provides insight into the clinical impact of early cancer detection, and recent advances * Experts also reviewed data on the Nu.Q™ Vet Cancer Screening Test, providing opinion and guid...
